Immunovant remains a high-risk, high-reward play, hinging on the success of its next-gen candidate IMVT-1402. Click to read my latest analysis of IMVT stock.

A 56-year-old man was admitted to the hospital because of left lower abdominal pain and anemia. He had a 1-year history of ...

IgE, best known for mediating allergic reactions, may also shape cancer outcomes. Learn how this immune molecule could serve as both a biomarker and a basis for next-generation therapies.

KT-579, a potent, selective, oral degrader of IRF5, demonstrated broad activity across multiple preclinical models of lupus and rheumatoid ...

A comprehensive study mapped the dynamic glycosylation landscape of rat serum proteins, uncovering sex- and time-dependent ...

THE final countdown to the 2025 Inter-Guiana Games (IGG) begins this week as high-level sporting delegations from French Guiana and Suriname arrive in ...

Scientists have built an AI-powered clock called gtAge that reads your blood to reveal your true biological age.

KT-579, a potent, selective, oral degrader of IRF5, demonstrated broad activity across multiple preclinical models of lupus and rheumatoid arthritis (RA), with activity comparable or superior to appro ...

A comprehensive study mapped the dynamic glycosylation landscape of rat serum proteins, uncovering sex- and time-dependent variations with clear ...

Investing.com -- Jefferies in a note dated Wednesday has initiated coverage on Hansa Biopharma AB with a “buy” rating and a price target of SEK 100, citing momentum from its first-in-class ...

Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today presented positive topline data from Part 1 of ...

The third quarter 2025 financial results and business update will be discussed during a conference call and webcast presentation today at 1:30 pm CET/8:30 am ET. A webcast of the live call and replay ...